

Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



26 November 2018.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform you that one of the wholly owned subsidiaries of the Company has agreed to acquire 100% shares of Pola Pharma Inc., Japan, subject to completion of closing conditions, by way of cash consideration of 100 million Japanese Yen (approximately US\$ 1 million) subject to closing adjustments.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.

This is for your information and record.

Yours faithfully,
For Sun Pharmaceutical Industries Ltd

A handwritten signature in blue ink, appearing to read "A. I. Bhuta".

Ashok I. Bhuta
Compliance Officer

Encl: as above

Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

<p>a) Name of the target entity, details in brief such as size, turnover etc.;</p>	<p>i) Name of the Target: "Pola Pharma Inc." (Target)</p> <p>ii) Details of the Target: Pola pharma Inc., along with its wholly owned subsidiary, is engaged in the development, manufacture and commercialization of pharmaceutical products in Japan with focus on the dermatology segment. Pola Pharma's product portfolio includes branded and generic products which are commercialized in Japan by its own dedicated sales force.</p> <p>Jan-Dec 2017 Sales: 12,217 million JPY (consolidated) Net Loss: 837 million JPY (consolidated)</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";</p>	<p>NO.</p>
<p>c) Industry to which the entity being acquired belongs;</p>	<p>Pharmaceuticals.</p>
<p>d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</p>	<p>This acquisition would give commercial presence in the dermatology segment in Japan.</p>
<p>e) Brief details of any governmental or regulatory approvals required for the acquisition;</p>	<p>NO.</p>
<p>f) Indicative time period for completion of the acquisition;</p>	<p>On or before January 31, 2019, subject to completion of closing conditions.</p>
<p>g) Nature of consideration - whether cash consideration or share swap and details of the same;</p>	<p>Cash transaction.</p>
<p>h) Cost of acquisition or the price at which the shares are acquired;</p>	<p>100 million JPY subject to closing adjustment.</p>

i) Percentage of shareholding / control acquired and / or number of shares acquired;	Sun Pharma Global FZE, a wholly owned subsidiary of the Company has agreed to acquire 100% shares of the Target.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Brief background:</p> <p>Pola Pharma is a 100% owned subsidiary of Pola Orbis Holdings Group of Japan. Pola Pharma, along with its subsidiary is engaged in the commercialization of branded and generic pharmaceutical products in Japan. It also provides contract manufacturing services.</p> <p>Line of business: Pharmaceuticals</p> <p>Date of incorporation: January 5, 2007</p> <p>Consolidated Turnover of last 3 years: (million JPY) Jan-Dec 2015: 9,226 Jan-Dec 2016: 10,870 Jan-Dec 2017: 12,217</p> <p>Country in which the acquired entity has presence: Japan. Exports from Japan to other markets contribute less than 1% of total revenues.</p>